Lenvatinib fda approval date?

When did the FDA approve lenvatinib?

Lenvatinib (Lenvima) received FDA approval on February 13, 2015 for the treatment of differentiated thyroid cancer (DTC) that is refractory to radioactive iodine and has progressed following prior systemic therapies or is not eligible for such therapies. [1]

Why is the approval date sometimes shown differently?

If you see other dates, they usually reflect:
- Later label expansions (FDA approving additional indications for the same drug), not the original approval.
- Different review/approval events reported by secondary sources.

The original FDA approval date for lenvatinib is February 13, 2015. [1]

What FDA indication was lenvatinib first approved for?

At initial approval, lenvatinib was for differentiated thyroid cancer that is refractory to radioactive iodine (and that meets the relevant progression/therapy-eligibility criteria described in the approval). [1]

Source

[1] https://www.drugpatentwatch.com/p/lenvatinib-fda-approval/